Our Team

Dr. Tepper has over 30 years of experience in the biotechnology and pharmaceutical industry.  He has led drug discovery & drug development programs that span a wide range of therapeutic areas including Oncology, Immunology, Rheumatology, Endocrinology, Metabolic Diseases, CNS, Inflammation and Pain. Following a 15-year career in large Pharma R&D, in 2002 Dr Tepper left large Pharma to become a serial entrepreneur where he founded multiple successful biotech companies.  In leading these companies, he served on the executive management team, helping to execute on the business & commercialization plan. In the last 15 years, Dr. Tepper has raised over $200M in capital for his ventures. He has taken two of his companies’ public (Corbus Pharmaceuticals and RXi Pharmaceuticals) and sold another company (Primatope sold to Kiniksa) in a trade sale.  

Dr. Tepper earned a Ph.D. in Biochemistry & Biophysics from Columbia University, College of Physicians and Surgeons, New York, and a B.A in Chemistry with Highest Honors from Clark University, Worcester, Mass. He did his postdoctoral fellowship at University of Massachusetts Medical School, Worcester in the laboratory of Michael P. Czech. He has over 50 scientific publications and is the co-inventor of multiple drug related patents.

Dr. Marshall brings 25+ years of experience across all aspects of clinical research including translational, Phase 1-3, and post-marketing studies in academia, startup, and mid-sized biopharmaceutical companies. In biotech, Dr. Marshall has developed and led programs across multiple CNS disorders, both neurology and psychiatry, in rare disease, and in hepatology and pediatric oncology. Most recently, Dr. Marshall co-founded ProTara Therapeutics as Chief Medical Officer, a clinical-stage rare disease company recently listed on NASDAQ. Prior to that, he held medical leadership roles of increasing responsibility at Sepracor, Sunovion, Euthymics, Neurovance, and Retrophin.

Dr. Marshall earned his MD at Johns Hopkins University and completed his Psychiatry residence at Columbia University, where he attained Associate Professor before leaving to pursue therapeutics research in biotechnology. At Columbia, he was PI, Co-PI, or Advisor to ~30 research grants funded through NIH, nonprofits and industry, and he has published more than 130 peer-reviewed publications, book chapters or books in his fields of expertise.

Joanne has over 25 years of experience in the industry, from academic research in Multi-Organ Transplant Research space at the University of Western Ontario, through a distinguished  career in leadership roles at both  large and mid-sized CROs including PRA and Premier Research. Her experience ranges across clinical operations, project management, study start-up, resourcing, and therapeutics-driven oversight, always with a keen focus on customer accountability for study delivery.

Joanne currently provides sponsor-focused consulting to emerging biotech and small pharma companies on overall clinical operational strategy and execution, including building outsourcing methods, creating and growing operational teams, and best practices vendor engagement and oversight.

Dr. Zhang has over 25 years of experience in developing small molecules, conjugated peptides, small molecule-drug conjugates, and biologics including antibody-drug conjugates. Most recently he was the Chief Technical Officer of Vincerx Pharma, responsible for strategy, planning and execution of all CMC activities. Previously, Dr. Zhang was a Venture Partner at Velocity Pharmaceutical Development, where he played an integral role in the launching and development of several project-focused companies, including Menlo Therapeutics, Corsair and Spitfire. Early in his career, Dr. Zhang held various scientific and program leadership positions at Roche, Millennium Pharmaceuticals and Portola Pharmaceuticals, where he contributed to the discovery and development of several new molecular entities.

Dr. Zhang received his Ph.D. from the University of Maryland, College Park, in the field of synthetic organic chemistry, and pursued postdoctoral research at the University of California, Berkeley. He is an inventor on 55 issued US patents.

Dylan has served as a business development, alliance management, and corporate strategy leader at several clinical-stage life sciences companies. Previously, he was Head of Business Development at Corbus Pharmaceuticals (NASDAQ: CRBP). In that role, he helped lead a complete strategic overhaul for the company and closed several large business development deals, including licensing transactions in the US and overseas. In his role, he is responsible for expanding EuMentis’ corporate operations and financial strategy.

Dylan has a B.Sc. in Chemistry from the University of North Florida. He is completing his MBA at Indiana University – Kelley School of Business in 2025 and a Fellow at No Patient Left Behind.